Medicine
 |
|
24 june 2020 23:30:37 |
| Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer (BMC Health Services Research) |
|
Tweet The IMpassion130 trial demonstrated that adding atezolizumab to nanoparticle albumin-bound (nab)-paclitaxel improved the survival of patients with untreated, advanced, programmed death ligand 1 (PDL1)-positive... |
| 359 viewsCategory: Medicine |
 A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis (Arthritis Research & Therapy)Applying critical systems thinking to social prescribing: a relational model of stakeholder “buy-in” (BMC Health Services Research) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
